Research area · Circadian research

Peptides and sleep research, before the claims

Two peptides people often ask about in connection with sleep are DSIP, also listed as emideltide, and epitalon. Each has a guide that sets out what has been studied and what regulators concluded: DSIP and epitalon. This page shows where they stand legally. If you searched for “peptides for sleep”, this is the page for that research area.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
2 compoundsGuides published
Updated Nov 2026Dated on every page
DSIP EPITALON
Short answerResearch area · Updated 18 Nov 2026

Two peptides people often ask about in connection with sleep are DSIP, also listed as emideltide, and epitalon. Each has a guide that sets out the studies and the regulators’ conclusions; this page makes no statement about effects. Neither is an FDA-approved medicine.

The research so far

How did FDA’s advisory committee vote on DSIP and epitalon?

In July 2026, by press reports, the FDA's compounding advisory committee voted 7 to 6 against adding emideltide (DSIP) to the 503A bulks list, with one abstention. FDA has not posted minutes. It is not covered by the October 2026 HHS policy. [1] [4] [2]

The same committee voted to recommend adding epitalon to the 503A bulks list, against FDA staff's proposal, and the October 2026 HHS policy covers it under ten conditions. An advisory vote is not a rule, and the policy is not an approval. [1] [6] [2]

What can’t we say yet about DSIP and epitalon?

Saying what we don't know is part of the evidence.

What DSIP or epitalon do in people. This page makes no statement about effects; the two guides set out the studies and their limits.

Are DSIP and epitalon FDA-approved medicines? US and sport status

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
DSIPNot approvedFormerly FDA Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); FDA advisory committee voted against listing (Jul, press-reported); not in the HHS policyNot named; check with your anti-doping body
EpitalonNot approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetNot named; S0 covers unapproved substances

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Did the FDA's advisory committee recommend DSIP?

No. By press reports, the compounding advisory committee voted against emideltide (DSIP) in July 2026, and the October HHS policy does not cover it.

Where is the evidence review?

In the DSIP guide and the epitalon guide. Each lists its sources and evidence tiers; this page shows legal status only.

Sources

  1. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting page, 23–24 July 2026: agenda, voting questions and FDA briefing (no minutes posted as of 17 November 2026). www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  2. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf
  3. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
  4. American Med Spa Association. FDA advisory committee recommends adding six of seven peptides to compounding list. News report of the vote counts, July 2026. www.americanmedspa.org/news/fda-advisory-committee-recommends-adding-six-of-seven-peptides-to-compounding-list/
  5. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  6. U.S. Department of Health and Human Services. Enforcement discretion policy, Appendix B: peptide identities and justifications, October 2026 (records the July 2026 committee outcome for each of the six peptides). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only